IBRN vs. CNCR

Last updated Apr 2, 2026

Compare and contrast key facts about iShares Neuroscience and Healthcare ETF (IBRN) and Loncar Cancer Immunotherapy ETF (CNCR).

IBRN and CNCR are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. IBRN is a passively managed fund by iShares that tracks the performance of the NYSE FactSet Global Neuro Biopharma and MedTech Index. It was launched on Aug 24, 2022. CNCR is a passively managed fund by Exchange Traded Concepts that tracks the performance of the Loncar Cancer Immunotherapy Index. It was launched on Oct 13, 2015. Both IBRN and CNCR are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.

Performance

IBRN vs. CNCR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in iShares Neuroscience and Healthcare ETF (IBRN) and Loncar Cancer Immunotherapy ETF (CNCR). The values are adjusted to include any dividend payments, if applicable.

IBRN vs. CNCR - Yearly Performance Comparison

	2026 (YTD)
IBRN iShares Neuroscience and Healthcare ETF	2.78%
CNCR Loncar Cancer Immunotherapy ETF	0.00%

Returns By Period

IBRN

• 1D: 1.00%
• 1M: 4.90%
• YTD: 2.99%
• 6M: 25.12%
• 1Y: 56.67%
• 3Y*: 12.28%
• 5Y*: —
• 10Y*: —

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

IBRN vs. CNCR - Expense Ratio Comparison

IBRN has a 0.47% expense ratio, which is lower than CNCR's 0.79% expense ratio.

CNCR

Loncar Cancer Immunotherapy ETF

IBRN

iShares Neuroscience and Healthcare ETF

Return for Risk

IBRN vs. CNCR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IBRN

IBRN Risk / Return Rank: 87
IBRN Sharpe Ratio Rank: 88
IBRN Sortino Ratio Rank: 89
IBRN Omega Ratio Rank: 81
IBRN Calmar Ratio Rank: 90
IBRN Martin Ratio Rank: 87

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IBRN vs. CNCR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares Neuroscience and Healthcare ETF (IBRN) and Loncar Cancer Immunotherapy ETF (CNCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	IBRN	CNCR	Difference
Sharpe ratio Return per unit of total volatility	1.96	—	—
Sortino ratio Return per unit of downside risk	2.64	—	—
Omega ratio Gain probability vs. loss probability	1.33	—	—
Calmar ratio Return relative to maximum drawdown	3.27	—	—
Martin ratio Return relative to average drawdown	11.55	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	IBRN	CNCR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.96	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.37	—	—

Dividends

IBRN vs. CNCR - Dividend Comparison

IBRN's dividend yield for the trailing twelve months is around 0.96%, while CNCR has not paid dividends to shareholders.

	TTM	2025	2024	2023
IBRN iShares Neuroscience and Healthcare ETF	0.96%	0.99%	0.40%	0.06%
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%

Drawdowns

IBRN vs. CNCR - Drawdown Comparison

The maximum IBRN drawdown since its inception was -35.38%, which is greater than CNCR's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for IBRN and CNCR.

Drawdown Indicators

	IBRN	CNCR	Difference
Max Drawdown Largest peak-to-trough decline	-35.38%	0.00%	-35.38%
Max Drawdown (1Y) Largest decline over 1 year	-15.44%	—	—
Current Drawdown Current decline from peak	-0.74%	0.00%	-0.74%
Average Drawdown Average peak-to-trough decline	-10.19%	0.00%	-10.19%
Ulcer Index Depth and duration of drawdowns from previous peaks	4.37%	—	—

Volatility

Volatility by Period

	IBRN	CNCR	Difference
Volatility (1M) Calculated over the trailing 1-month period	12.02%	—	—
Volatility (6M) Calculated over the trailing 6-month period	19.63%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	29.38%	0.00%	+29.38%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	25.39%	0.00%	+25.39%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	25.39%	0.00%	+25.39%